无化疗方案治疗EB病毒阳性弥漫性大B细胞性淋巴瘤1例  

A patient with EB virus-positive diffuse large B-cell lymphoma treated with Chemo-free regimenand literature review

作　　者：刘姗 杨航[1] 李志铭[1] Liu Shan;Yang Hang;Li Zhiming(Department of Medical Oncology,Sun Yat-sen University Cancer Center,Guangzhou,510060,China)

机构地区：[1]中山大学肿瘤防治中心肿瘤科,广州510060

出　　处：《中华转移性肿瘤杂志》2022年第1期69-71,共3页Chinese Journal of Metastatic Cancer

摘　　要：目的EB病毒阳性弥漫性大B细胞淋巴瘤(DLBCL)传统的R-CHOP方案获益并不理想,本病例利用利妥昔单抗+泽布替尼+来那度胺+PD-1抗体治疗1例80岁女性EB病毒阳性DLBCL患者。方法应用PET-CT评估此联合用药方案治疗前后的肿瘤代谢变化。结果患者经此联合用药治疗后,PET-CT评估疗效4个周期后患者达到完全缓解。结论此联合用药方案为EB病毒阳性DLBCL提供了一种治疗选择,特别是老年性EB病毒阳性DLBCL,既有疗效且耐受性好。Objective The benefit of conventional R-CHOP(rituximab+zanubrutinib+lenalidomide)regimen for EB virus-positive diffuse large B cell lymphoma(DLBCL)was not ideal.In this case,we treated an 80-year-old female patient with EBV-positive DLBCL with R-CHOP+PD-1 antibodyregimen.Methods PET-CT was used to evaluate the changes of tumor metabolism in patient treatment with this combination regimen.Results The patient achieved complete remission after 4 cycles of treatment.Conclusion This combination regimen provides an effective and well-tolerated treatment option for EBV-positive DLBCL,especially in elderly EBV-positive DLBCL.

关 键 词：EB病毒阳性 弥漫性大B细胞性淋巴瘤 免疫治疗 靶向治疗 

分 类 号：R733.1[医药卫生—肿瘤]